<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />



<meta name="date" content="2026-02-13" />

<title>SMSPHARMA</title>

<script src="rmdlib/header-attrs-2.30/header-attrs.js"></script>
<script src="rmdlib/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="rmdlib/bootstrap-3.3.5/css/flatly.min.css" rel="stylesheet" />
<script src="rmdlib/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="rmdlib/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="rmdlib/navigation-1.1/tabsets.js"></script>
<script src="rmdlib/accessible-code-block-0.0.1/empty-anchor.js"></script>
<link href="rmdlib/font-awesome-6.4.0/css/all.min.css" rel="stylesheet" />
<link href="rmdlib/font-awesome-6.4.0/css/v4-shims.min.css" rel="stylesheet" />
<meta name="description" content="Indian equities analysis, margin reports, risk, etc..." />
<meta property="og:image" content="https://avatars3.githubusercontent.com/u/21966469?s=400&v=4" />

<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>










<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
details > summary > p:only-child {
  display: inline;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark the anchor link active (and if it's in a dropdown, also mark that active)
  var dropdown = menuAnchor.closest('li.dropdown');
  if (window.bootstrap) { // Bootstrap 4+
    menuAnchor.addClass('active');
    dropdown.find('> .dropdown-toggle').addClass('active');
  } else { // Bootstrap 3
    menuAnchor.parent().addClass('active');
    dropdown.addClass('active');
  }

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before, .tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "\e259";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "\e258";
  font-family: 'Glyphicons Halflings';
  border: none;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->




</head>

<body>


<div class="container-fluid main-container">




<div class="navbar navbar-inverse  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-bs-toggle="collapse" data-target="#navbar" data-bs-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">StockViz</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-globe"></span>
     
    Macro
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-bnd.html">Fixed Income</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cur.html">Currencies</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/macro/rp-cmdy.html">Commodities</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-arrows-v"></span>
     
    52w H&amp;L
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/52wk-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-rocket"></span>
     
    ATH
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/ath-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-magnet"></span>
     
    Drawdowns
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/drawdowns-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-train"></span>
     
    Streaks
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-IN.html">India</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/streaks-US.html">US</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-hand-pointer-o"></span>
     
    Indian Indices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-risk.html">Performance Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-IN.html">Index Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-MKT-CAP.html">Classification Changes</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-industry.html">Industry Metrics</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-syn.html">Synthetic Indices</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-vol-NIFTY.html">NIFTY Volatility</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/index/rp-valuations.html">Valuations</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports01/eq/results-IN.html">Result Dates</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/eq-in/rp-margin.html">Margin Report</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-shopping-bag"></span>
     
    Funds
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports03/mf/rp-IN.html">Indian Mutual Funds</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports03/pms/rp-IN.html">Indian PMS</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-risk.html">US ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-sector.html">US Sector ETFs</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-country.html">Country $ ETFs</a>
    </li>
  </ul>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" data-bs-toggle="dropdown" aria-expanded="false">
    <span class="fa fa-percent"></span>
     
    Fama-French
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-industry.html">Industry</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-factors.html">Factors</a>
    </li>
    <li>
      <a href="https://stockviz.github.io/reports02/etf-us/rp-fama-french-regression.html">Regressions</a>
    </li>
  </ul>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        <li>
  <a href="https://stockviz.biz">
    <span class="fa fa-home"></span>
     
  </a>
</li>
<li>
  <a href="https://stockviz.substack.com">
    <span class="fa fa-envelope-o"></span>
     
  </a>
</li>
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">SMSPHARMA</h1>
<h3 class="subtitle">Equity Metrics</h3>
<h4 class="date">February 13, 2026</h4>

</div>


<div id="sms-pharmaceuticals-limited" class="section level1">
<h1>SMS Pharmaceuticals Limited</h1>
<p><a href="/reports01/index/industry/rp-Pharmaceuticals.html">Pharmaceuticals</a></p>
<div id="annual-returns" class="section level2">
<h2>Annual Returns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SMSPHARMA.fan.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SMSPHARMA.annret.png" /></p>
</div>
<div id="cumulative-returns-and-drawdowns" class="section level2">
<h2>Cumulative Returns and Drawdowns</h2>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SMSPHARMA.cumret.png" /></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SMSPHARMA.sma.cumret.png" /></p>
<p><br><br></p>
</div>
<div id="fundamentals" class="section level2">
<h2>Fundamentals</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SMSPHARMA.eps.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SMSPHARMA.RevenueFromOperations.png" /></p>
<p><br><br></p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SMSPHARMA.ebit.png" /></p>
<p><br><br></p>
</div>
<div id="ownership" class="section level2">
<h2>Ownership</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SMSPHARMA.ownership.png" /></p>
<p><br><br></p>
</div>
<div id="margined" class="section level2">
<h2>Margined</h2>
<p><br />
</p>
<p><img src="https://etf-us-risk-plots.stockviz.biz/in.SMSPHARMA.mtf.png" /></p>
<p><br><br></p>
<p><br />
</p>
</div>
<div id="ai-summary" class="section level2">
<h2>AI Summary</h2>
<p><em>asof: 2025-12-08 </em></p>
<p>Based on a detailed analysis of the documents submitted by <strong>SMS Pharmaceuticals Limited (SMSPHARMA)</strong>‚Äîincluding Q2 FY26 financial results, auditors‚Äô review reports, statement of deviation in fund utilization, and voting outcomes of the 37th AGM‚Äîhere is a <strong>comprehensive summary</strong> of the company‚Äôs <strong>headwinds, tailwinds, growth prospects, and key risks</strong>, tailored for investors and stakeholders.</p>
<hr />
<div id="company-overview" class="section level6">
<h6>üìå <strong>Company Overview</strong></h6>
<ul>
<li><strong>Ticker</strong>: SMSPHARMA (BSE: 532815)</li>
<li><strong>Sector</strong>: Pharmaceuticals (APIs and Intermediates)</li>
<li><strong>Core Business</strong>: Manufacturing of Active Pharmaceutical Ingredients (APIs) and intermediates; operates as a <strong>single reportable segment under Ind AS 108</strong>.</li>
<li><strong>Key Subsidiaries/Associates</strong>:
<ul>
<li>VKT Pharma Pvt. Ltd.¬†(Associate, 34.83% stake)</li>
<li>SMS Peptides Pvt. Ltd.¬†(Subsidiary)</li>
<li>Chemo SMS Enterprises SL (Joint Venture, no current operations)</li>
</ul></li>
</ul>
<hr />
</div>
<div id="financial-highlights-q2-h1-fy26-unaudited-quarter-ended-30-sept-2025" class="section level6">
<h6>üîç <strong>Financial Highlights (Q2 &amp; H1 FY26, Unaudited) ‚Äì Quarter Ended 30 Sept 2025</strong></h6>
<table>
<thead>
<tr class="header">
<th>Metric</th>
<th>Q2 FY26 (‚Çπ Cr)</th>
<th>Q1 FY26 (‚Çπ Cr)</th>
<th>YoY Growth</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Standalone Revenue</strong></td>
<td>2,424.30</td>
<td>1,960.47</td>
<td>+23.6% QoQ, +23.3% YoY</td>
</tr>
<tr class="even">
<td><strong>Net Profit (Standalone)</strong></td>
<td>251.43</td>
<td>182.08</td>
<td>+38% QoQ, +76% YoY</td>
</tr>
<tr class="odd">
<td><strong>EPS (Basic)</strong></td>
<td>‚Çπ2.82</td>
<td>‚Çπ2.05</td>
<td>+37.6% QoQ</td>
</tr>
<tr class="even">
<td><strong>Consolidated Net Profit</strong></td>
<td>253.13</td>
<td>204.91</td>
<td>+23.5% QoQ, +79.7% YoY</td>
</tr>
<tr class="odd">
<td><strong>Earnings Per Share (Consolidated)</strong></td>
<td>‚Çπ2.84</td>
<td>‚Çπ2.31 (Q1)</td>
<td>+22.9% QoQ</td>
</tr>
</tbody>
</table>
<blockquote>
<p>üí° <strong>Note</strong>: The first half (H1) of FY26 reported consolidated net profit of ‚Çπ458.03 Cr, already <strong>~66% of previous full-year profit of ‚Çπ674 Cr (FY25)</strong>‚Äîindicating accelerated earnings momentum.</p>
</blockquote>
<hr />
</div>
<div id="tailwinds-positive-catalysts" class="section level6">
<h6>üöÄ <strong>Tailwinds &amp; Positive Catalysts</strong></h6>
<div id="strong-revenue-and-margin-expansion" class="section level9">
<p class="heading">1. <strong>Strong Revenue and Margin Expansion</strong></p>
<ul>
<li>Revenues show <strong>strong sequential and YoY growth</strong>, suggesting improved demand or scale-up in operations.</li>
<li>Revenue growth (23‚Äì24%) outpaces cost increases, leading to <strong>expanding profitability</strong>.</li>
<li><strong>Gross profit margin (approx. 56%)</strong> improved due to better control of material costs and favorable inventory movements.</li>
</ul>
</div>
<div id="robust-cash-generation" class="section level9">
<p class="heading">2. <strong>Robust Cash Generation</strong></p>
<ul>
<li>Operating cash inflow (H1): ‚Çπ5,088 Cr (up 8.8% YoY).</li>
<li>Improved working capital management with:
<ul>
<li>Inventory increase under control (+‚Çπ3,266 Cr vs.¬†huge YoY drop last year).</li>
<li>Trade receivables up but aligned with revenue jump.</li>
<li><strong>Cash &amp; cash equivalents surged to ‚Çπ994.90 Cr</strong> (from ‚Çπ414 Cr at start of year), giving strong liquidity.</li>
</ul></li>
</ul>
</div>
<div id="strategic-capital-expenditure-capacity-expansion" class="section level9">
<p class="heading">3. <strong>Strategic Capital Expenditure &amp; Capacity Expansion</strong></p>
<ul>
<li>Funds raised via <strong>preferential issue (‚Çπ114.3 Cr)</strong> are being used for:
<ul>
<li><strong>Phased expansion</strong> of production capacity.</li>
<li>Installation of utilities and recovery systems.</li>
<li><strong>Backward integration into KSMs (Key Starting Materials)</strong> ‚Äì critical for API cost control, quality, and supply chain resilience.</li>
</ul></li>
<li>Partial funds temporarily used in working capital to reduce financing costs ‚Äì approved by Audit Committee with clear intent to reallocate.</li>
</ul>
</div>
<div id="investor-confidence-agm-vote-ratification" class="section level9">
<p class="heading">4. <strong>Investor Confidence: AGM Vote Ratification</strong></p>
<ul>
<li><strong>All 7 resolutions passed with overwhelming support (99.98‚Äì100% voting in favor)</strong> including re-appointment of promoters (Trilok &amp; Vamsi Potluri).</li>
<li>Approval for <strong>material RPT with VKT Pharma (an associate)</strong> despite promoter interest‚Äîindicates market acceptance of synergies.</li>
<li>Promoters hold <strong>~66% ownership (58.75M shares out of 88.65M total shares)</strong>‚Äîensures strategic continuity.</li>
</ul>
</div>
<div id="associate-performance-adds-value" class="section level9">
<p class="heading">5. <strong>Associate Performance Adds Value</strong></p>
<ul>
<li>VKT Pharma Pvt. Ltd.¬†reported:
<ul>
<li>Net Profit after Tax (Q2 FY26): ‚Çπ52.67 Cr</li>
<li>Full Half: ‚Çπ562.57 Cr ‚Äî implies <strong>~12x jump in Q2 vs Q1</strong> (from ‚Çπ48k to ‚Çπ52.67 Cr)</li>
</ul></li>
<li>This <strong>massive uptick in associate profitability</strong> contributed <strong>‚Çπ18.34 Cr</strong> to consolidated net profit.</li>
<li>SMS Peptides yet to scale, showing small losses, but future potential in peptide APIs.</li>
</ul>
<hr />
</div>
</div>
<div id="headwinds-risks" class="section level6">
<h6>‚ö†Ô∏è <strong>Headwinds &amp; Risks</strong></h6>
<div id="declining-fixed-assets-high-capex-need" class="section level9">
<p class="heading">1. <strong>Declining Fixed Assets &amp; High Capex Need</strong></p>
<ul>
<li><strong>PPE (Property, Plant, Equipment)</strong> declined from ‚Çπ5,308 Cr (Mar-25) to ‚Çπ5,139 Cr (Sep-25).
<ul>
<li>However, <strong>Capital Work-in-Progress (CWIP) rose sharply</strong> from ‚Çπ3,467 Cr to ‚Çπ5,359 Cr ‚Äî this explains the drop in PPE.</li>
<li><strong>Interpretation</strong>: The drop is <strong>not necessarily negative</strong>‚Äîit‚Äôs a <strong>reclassification of assets under development</strong>, suggesting expansion.</li>
</ul></li>
<li>Still, high capex can pressure debt and ROI over short term.</li>
</ul>
</div>
<div id="inventory-build-up-liquidity-risk" class="section level9">
<p class="heading">2. <strong>Inventory Build-Up &amp; Liquidity Risk</strong></p>
<ul>
<li><strong>Inventories rose to ‚Çπ3,173.94 Cr (up ‚Çπ3,266 Cr YoY)</strong> ‚Äî faster than revenue growth.</li>
<li>While this could support future sales, <strong>overstock risks</strong> exist if demand slows or regulatory approvals for new products face delays.</li>
</ul>
</div>
<div id="debt-levels-are-rising" class="section level9">
<p class="heading">3. <strong>Debt Levels Are Rising</strong></p>
<table>
<thead>
<tr class="header">
<th>Indicator</th>
<th>As of Sep 2025</th>
<th>As of Mar 2025</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Short-term Borrowings</td>
<td>‚Çπ2,030 Cr</td>
<td>‚Çπ1,714 Cr</td>
</tr>
<tr class="even">
<td>Long-term Borrowings</td>
<td>‚Çπ1,213 Cr</td>
<td>‚Çπ1,394 Cr</td>
</tr>
<tr class="odd">
<td>Total Debt</td>
<td>‚Çπ3,243 Cr</td>
<td>‚Çπ3,108 Cr</td>
</tr>
</tbody>
</table>
<ul>
<li><strong>Net Debt Position Improved</strong>: Cash up significantly ‚Üí <strong>Net Debt likely down</strong>.</li>
<li>But <strong>increased leverage in H1</strong> (net cash outflow in financing: -‚Çπ3,771 Cr) raises concerns on funding mix.</li>
</ul>
</div>
<div id="regulatory-compliance-risks-especially-for-rpts" class="section level9">
<p class="heading">4. <strong>Regulatory &amp; Compliance Risks (Especially for RPTs)</strong></p>
<ul>
<li><strong>Material RPT with VKT Pharma</strong> approved, but <strong>SEBI norms are strict</strong> on transparency.</li>
<li>Although approved by public shareholders (99.996% in favor), any <strong>future operational interdependency</strong> or pricing disputes could trigger scrutiny.</li>
<li><strong>Chemo SMS SL (JV)</strong> inactive‚Äîcould lead to future impairment or dilution review.</li>
</ul>
</div>
<div id="subsidiary-performance-lagging" class="section level9">
<p class="heading">5. <strong>Subsidiary Performance Lagging</strong></p>
<ul>
<li><strong>SMS Peptides Pvt. Ltd.</strong> reported net loss of ‚Çπ3.12 Cr (Q2 FY26) ‚Äî cumulative loss ‚Çπ15.35 Cr (H1).</li>
<li>Peptide therapeutics is a high-potential niche, but requires sustained investment and long gestation.</li>
<li>Risk of prolonged losses unless turnaround or commercialization milestones are achieved.</li>
</ul>
<hr />
</div>
</div>
<div id="growth-prospects-strategic-moves" class="section level6">
<h6>üìà <strong>Growth Prospects &amp; Strategic Moves</strong></h6>
<table>
<colgroup>
<col width="42%" />
<col width="57%" />
</colgroup>
<thead>
<tr class="header">
<th>Area</th>
<th>Insight</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>1. Backward Integration into KSMs</strong></td>
<td>Reduces dependency on imported raw materials, improves margins, secures supply chain. High impact over 2‚Äì3 years.</td>
</tr>
<tr class="even">
<td><strong>2. Expansion of API Capacity</strong></td>
<td>Supports increasing demand from global pharma companies (especially US/EU/ROW markets).</td>
</tr>
<tr class="odd">
<td><strong>3. Associate Turnaround (VKT Pharma)</strong></td>
<td>VKT‚Äôs sudden EBITDA/Profit surge is a <strong>positive surprise</strong>‚Äîwatch for sustainability and whether it‚Äôs export-led or domestic sales.</td>
</tr>
<tr class="even">
<td><strong>4. Financial Strength &amp; Flexibility</strong></td>
<td>High cash reserves allow flexibility for acquisitions, R&amp;D, dividend policy, or further capex.</td>
</tr>
<tr class="odd">
<td><strong>5. Dividend &amp; Shareholder Returns</strong></td>
<td>Paid <strong>‚Çπ0.40/share dividend</strong> for FY25 (~45% payout ratio)‚Äîbalanced between growth reinvestment and returns.</td>
</tr>
<tr class="even">
<td><strong>6. Segment Focus</strong></td>
<td>Single business segment keeps strategy simple and transparent ‚ÄîÂà©‰∫é scaling operations.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="valuation-market-position-inferred" class="section level6">
<h6>üßÆ <strong>Valuation &amp; Market Position (Inferred)</strong></h6>
<ul>
<li><strong>Market Cap Est. (as of late FY25)</strong>: ~‚Çπ4,000‚Äì4,500 Cr range (stock-specific data not provided, but based on typical P/E for mid-cap API players).</li>
<li>EPS for H1 FY26: ‚Çπ5.13 (consolidated) ‚Üí implies <strong>full-year EPS of ~‚Çπ10.2‚Äì10.5</strong>.</li>
<li>If trading at ~40‚Äì45x earnings ‚Äî fair valuation in current market context given growth.</li>
</ul>
<hr />
</div>
<div id="summary-key-takeaways" class="section level6">
<h6>‚úÖ <strong>Summary: Key Takeaways</strong></h6>
<table>
<colgroup>
<col width="40%" />
<col width="60%" />
</colgroup>
<thead>
<tr class="header">
<th>Category</th>
<th>Assessment</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>‚úÖ Tailwinds</strong></td>
<td>Strong revenue growth, margin improvement, sharp rise in associate profit (VKT), massive cash buildup, supportive promoter ownership, strategic capacity expansion, and RPT approval.</td>
</tr>
<tr class="even">
<td><strong>‚ö†Ô∏è Headwinds</strong></td>
<td>Rising inventory, high reliance on associate profitability, ongoing capex pressure, and inactivity in JV (Chemo SMS).</td>
</tr>
<tr class="odd">
<td><strong>üîç Risks</strong></td>
<td>1. <strong>Dependency on VKT‚Äôs performance</strong> ‚Äì sudden spike needs scrutiny<br>2. <strong>Execution risk in capex and KSM integration</strong><br>3. <strong>Supply chain/regulatory delays</strong> in global markets<br>4. <strong>Debt service and interest cost</strong> pressure if rates remain high</td>
</tr>
<tr class="even">
<td><strong>üìà Growth Prospects</strong></td>
<td>Favorable: Scale-up in API production, KSM integration, peptide ambitions (long-term), and strong domestic/global demand post-pandemic.</td>
</tr>
</tbody>
</table>
<hr />
</div>
<div id="final-verdict-accumulate-with-caution" class="section level6">
<h6>üìå Final Verdict: <strong>Accumulate with Caution</strong></h6>
<blockquote>
<p><strong>SMSPHARMA is on a clear growth trajectory</strong>‚Äîstrong standalone performance, improving cash flows, strategic capex, and a high-performing associate have boosted earnings momentum. The company is using its preferential capital efficiently and maintaining good governance (evident in high AGM voting support).</p>
</blockquote>
<blockquote>
<p><strong>Investors should monitor</strong>: - Sustainability of VKT Pharma‚Äôs profitability. - Progress on KSM backward integration. - Inventory turnover and debt levels in next quarter. - Regulatory developments in export markets (especially EU/FDA).</p>
</blockquote>
<p><strong>Recommendation</strong>:<br />
üü¢ <strong>Accumulate on dips</strong> at reasonable valuations. Suitable for <strong>medium-to-long-term investors</strong> in the selective API space with exposure to integrated manufacturers.</p>
<hr />
<blockquote>
<p><strong>Data Cut-off</strong>: November 08, 2025 (Board Meeting &amp; Filing Date)<br />
<strong>Next Catalyst Watch</strong>: Q3 FY26 Results, FDA/WHO inspection updates, KSM plant commissioning.</p>
</blockquote>
<p>Let me know if you‚Äôd like a <strong>DCF valuation model</strong>, <strong>peer comparison</strong>, or <strong>stock screening checklist</strong> for SMSPHARMA.</p>
</div>
</div>
</div>

&nbsp;
&nbsp;
<hr />
<p style="text-align: center;">Copyright &copy; 2023 SAS Data Analytics Pvt. Ltd. All rights reserved.</p>
<p style="text-align: center;"><a href="https://github.com/stockviz/reports/issues">&#x1F41E;</a></p>



</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
